Literature DB >> 12870678

Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment.

Marcos A Espinal.   

Abstract

Mesh：

Year:  2003        PMID： 12870678

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  14 in total

1.  Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam.

Authors:  M Caws; Phan Minh Duy; Dau Quang Tho; Nguyen Thi Ngoc Lan; Dai Viet Hoa; Jeremy Farrar
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

2.  In-house phage amplification assay is a sound alternative for detecting rifampin-resistant Mycobacterium tuberculosis in low-resource settings.

Authors:  Norberto Símboli; Howard Takiff; Ruth McNerney; Beatriz López; Anandi Martin; Juan Carlos Palomino; Lucía Barrera; Viviana Ritacco
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 3.  The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach.

Authors:  S Basu; A P Galvani
Journal:  Epidemiol Infect       Date:  2008-07-07       Impact factor: 2.451

4.  Closing the book on Category II: time for individualized regimens for patients with recurrent tuberculosis.

Authors:  Sara C Auld; Neel R Gandhi; N Sarita Shah
Journal:  Int J Tuberc Lung Dis       Date:  2018-10-01       Impact factor: 2.373

5.  Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Authors:  Edward C Jones-López; Irene Ayakaka; Jonathan Levin; Nancy Reilly; Francis Mumbowa; Scott Dryden-Peterson; Grace Nyakoojo; Kevin Fennelly; Beth Temple; Susan Nakubulwa; Moses L Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Jerrold J Ellner; Peter G Smith; Roy D Mugerwa
Journal:  PLoS Med       Date:  2011-03-15       Impact factor: 11.069

6.  Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco.

Authors:  Kelly E Dooley; Ouafae Lahlou; Iraqi Ghali; Janine Knudsen; My Driss Elmessaoudi; Imad Cherkaoui; Rajae El Aouad
Journal:  BMC Public Health       Date:  2011-02-28       Impact factor: 3.295

7.  Tuberculosis chemotherapy in the 21 century: Back to the basics.

Authors:  Jyotsna M Joshi
Journal:  Lung India       Date:  2011-07

8.  Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008.

Authors:  Eugene Lam; Sriprapa Nateniyom; Sara Whitehead; Amornrat Anuwatnonthakate; Patama Monkongdee; Apiratee Kanphukiew; Jiraphan Inyaphong; Wanlaya Sitti; Navarat Chiengsorn; Saiyud Moolphate; Suporn Kavinum; Narin Suriyon; Pranom Limsomboon; Junya Danyutapolchai; Chalinthorn Sinthuwattanawibool; Laura Jean Podewils
Journal:  Emerg Infect Dis       Date:  2014-03       Impact factor: 6.883

Review 9.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

10.  Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa.

Authors:  Jeffrey K Hom; Bingxia Wang; Senica Chetty; Janet Giddy; Matilda Mazibuko; Jenny Allen; Rochelle P Walensky; Elena Losina; Kenneth A Freedberg; Ingrid V Bassett
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.